130995-44-7

Upstream product

• 55362-80-6 9-bromononan-1-ol 

Downstream Products

• 1416069-18-5 (3-(8-(1,3-dioxolan-2-yl)octyloxy)phenyl)(phenyl)methanone 
• 1416069-46-9 (3-((8-(1,3-dioxolan-2-yl)octyl)oxy)-4-methylphenyl)-methanol 
• 1416069-24-3 3-(8-(1,3-dioxolan-2-yl)octyloxy)benzaldehyde 
• 1416069-36-7 (3-((8-(1,3-dioxolan-2-yl)octyl)oxy)-5-bromophenyl)methanol 
• 1416069-37-8 3-((8-(1,3-dioxolan-2-yl)octyl)oxy)-5-bromobenzaldehyde 
• 1416069-19-6 (3-(8-(1,3-dioxolan-2-yl)octyloxy)phenyl)(phenyl)methanol 
• 1416069-20-9 2-(8-(3-(azido(phenyl)methyl)phenoxy)octyl)-1,3-dioxolane 
• 1416069-21-0 (3-(8-(1,3-dioxolan-2-yl)octyloxy)phenyl)(phenyl)methanamine 
• 1416069-22-1 (R)-quinuclidin-3-yl (3-(8-(1,3-dioxolan-2-yl)octyloxy)phenyl)(phenyl)methylcarbamate 
• 1416069-23-2 (R)-quinuclidin-3-yl (3-(9-oxononyloxy)phenyl)(phenyl)-methylcarbamate 
• 1416065-91-2 (R)-quinuclidin-3-yl (3-(9-((R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)nonyloxy)phenyl)-(phenyl)methylcarbamate 
• 1416069-25-4 (3-(8-(1,3-dioxolan-2-yl)octyloxy)phenyl)(thiophen-2-yl)methanol 
• 1416069-35-6 benzyl 3-((8-(1,3-dioxolan-2-yl)octyl)oxy)-5-bromobenzoate 
• 876143-49-6 (2-Bromophenyl)carbamic Acid 1-(8-[1,3]Dioxolan-2-yloctyl)piperidin-4-yl Ester 

Relevant academic research and scientific papers

Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)

The targeting of both the muscarinic and β-adrenergic pathways is a well validated therapeutic approach for the treatment of chronic obstructive pulmonary disease (COPD). In this communication we report our effort to incorporate two pharmacologies into a single chemical entity, whose characteristic must be suitable for a once daily inhaled administration. Contextually, we aimed at a locally acting therapy with limited systemic absorption to minimize side effects. Our lung-tailored design of bifunctional compounds that combine the muscarinic and β-adrenergic pharmacologies by the elaboration of the muscarinic inhibitor 7, successfully led to the potent, pharmacologically balanced muscarinic antagonist and β2 agonist (MABA) 13.

BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

The present invention relates to compounds of general formula (I), acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients.

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients.

The synthesis of natural R-(-)enantiomers from three galbanum resin macrolides

The three macrolides 1, 2 and 3 isolated from galbanum resin were synthesized starting from ω-bromoacetals 9. The key step is the buffered intramolecular Wittig reaction of the ylides 14 and 23 to afford the α,β-unsaturated lactones 15, 16 and 24. Hydrogenation of these lactones gives the title macrolides in (R)-configuration.